| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Development Officer | Chief Development Officer
1 company
Christopher Yea is Chief Development Officer at KALV. Christopher Yea's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $6.0M at current prices.
Historically, Christopher Yea's trades have earned a middling insider score of 53/100 across 27 rated trades. Over a 12-month horizon, 28.6% of those trades were profitable, with an average 12-month return of -21.6%.
The KALV filings lean toward selling, a net 238,603 shares.
Christopher Yea has 50 Form 4 filings on record from November 2016 to November 2025, all as Chief Development Officer at KalVista Pharmaceuticals (KALV), 2016–2025.
The 99 reported transactions were 48 open-market sales, 33 option exercises, 15 option or other derivative awards and 3 stock awards.
Counted by filing, the open-market trades come to no purchases and 38 sales worth about $3.8M.
The largest open-market sale was 39,886 shares of KALV at an average $15.01 on February 14, 2024, about $599K. Twelve months later KALV was down 34%.
None of the 21 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 24, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Development Officer | Sale+OE | 4,331 | $13.45 | $58,256.28 | -1.9% | +16.5% | - | |
| Nov 18, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Development Officer | Sale+OE | 2,683 | $14.48 | $38,848.23 | -2.0% | +5.0% | - | |
| Aug 25, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Development Officer | Sale+OE | 1,954 | $13.42 | $26,222.68 | -1.5% | +2.8% | - | |
| Aug 22, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Development Officer | Sale+OE | 2,362 | $13.22 | $31,232.25 | -1.8% | -2.9% | - | |
| Aug 18, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Development Officer | Sale+OE | 2,649 | $13.19 | $34,932.36 | -2.0% | +11.4% | - | |
| Jul 9, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Development Officer | Sell | 30,250 | $15.69 | $474,698.13 | -19.1% | -31.7% | - | |
| May 23, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Development Officer | Sale+OE | 1,926 | $11.31 | $21,781.71 | -1.9% | +13.0% | +133.6% | |
| May 22, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Development Officer | Sale+OE | 2,317 | $11.88 | $27,515.53 | -2.3% | +13.0% | +134.6% | |
| May 19, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Development Officer | Sale+OE | 2,600 | $11.84 | $30,791.28 | -2.6% | +10.5% | +121.8% | |
| Feb 24, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Development Officer | Sale+OE | 1,918 | $10.02 | $19,218.36 | -2.0% | +8.3% | +52.2% |